M. Y. Al-Marrawi

Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer

Wafik S El-Deiry, W. El-Deiry, Zhaohai Yang, 2013, Cancer biology & therapy.

Consolidation With Radiation or Concurrent Chemo-Radiation After Chemotherapy Results in Durable Complete Remissions of Isolated Nodal Recurrences of Urothelial Cancer: A Case Series and Review.

J. Drabick, H. Wagner, M. Y. Al-Marrawi, 2016, Clinical genitourinary cancer.

The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts).

N. Agarwal, B. Rini, M. Tan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pazopanib for the treatment of renal cancer

B. Rini, M. Y. Al-Marrawi, 2011, Expert opinion on pharmacotherapy.

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

T. Choueiri, N. Agarwal, B. Rini, 2013, Targeted Oncology.

Effect of topical vaginal androgens in a woman on the testosterone levels of her sexual partner with prostate cancer.

J. Drabick, M. Y. Al-Marrawi, L. Cream, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erratum

B. Rini, M. Y. Al-Marrawi, 2011 .

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

T. Choueiri, N. Agarwal, B. Rini, 2013, Targeted Oncology.